EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Canagliflozin and iron metabolism in the CREDENCE trial

Akihiko Koshino iD, Hiddo J L Heerspink iD, Niels Jongs, Sunil V Badve, Clare Arnott iD, Bruce Neal, Meg Jardine, Kenneth W Mahaffey, Carol Pollock iD, Vlado Perkovic, Michael K Hansen, Stephan J L Bakker und 2 weitere

Nephrology Dialysis Transplantation · 01.04.2025 · 40 (4) · 696-706

DOI: 10.1093/ndt/gfae198 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 20.09.2024. Verfasst von Akihiko Koshino und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Canagliflozin, Iron, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Research and Development, Mitsubishi Tanabe Pharm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Studies in patients with heart failure have indicated that sodium-glucose cotransporter 2 (SGLT2) inhibitors increase iron use and enhance erythropoiesis. In this post hoc analysis of the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, we evaluated the effects of canagliflozin on iron metabolism in patients with chronic kidney disease (CKD) and whether the effects of canagliflozin on hemoglobin and cardiorenal outcomes were modified by iron deficiency.

Methods

We measured serum iron, total iron binding capacity (TIBC), transferrin saturation (TSAT) and ferritin at baseline and 12 months. The effects of canagliflozin, relative to placebo, on iron markers were assessed with analysis of covariance. Interactions between baseline iron deficiency, defined as TSAT <20%, and the effects of canagliflozin on hemoglobin and cardiorenal outcomes were evaluated with mixed effect models and Cox regression models, respectively.

Results

Of 4401 participants randomized in CREDENCE, 2416 (54.9%) had iron markers measured at baseline, of whom 924 (38.2%) were iron deficient. Canagliflozin, compared with placebo, increased TIBC by 2.1% [95% confidence interval (CI) 0.4, 3.8; P = .014] and decreased ferritin by 11.5% (95% CI 7.1, 15.7; P < .001) with no clear effect on serum iron or TSAT. Canagliflozin increased hemoglobin over the trial duration by 7.3 g/L (95% CI 6.2, 8.5; P < .001) and 6.7 g/L (95% CI 5.2, 8.2; P < .001) in patients with and without iron deficiency, respectively (P for interaction = .38). The relative effect of canagliflozin on the primary outcome of doubling of serum creatinine, kidney failure or death due to cardiovascular disease or kidney failure (hazard ratio 0.70, 95% CI 0.56, 0.87) was consistent regardless of iron deficiency (P for interaction = .83), as were effects on other cardiovascular and mortality outcomes (all P for interactions ≥0.10).

Conclusion

Iron deficiency is highly prevalent in patients with type 2 diabetes and CKD. Canagliflozin increased TIBC and decreased ferritin in patients with type 2 diabetes and CKD, suggesting increased iron utilization, and improved hemoglobin levels and clinical outcomes regardless of iron deficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CanagliflozinIronRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2HumansMaleFemaleMiddle AgedAgedDouble-Blind MethodFollow-Up StudiesPrognosisGlomerular Filtration RateBiomarkers

Stichwörter der Autor:innen

anemiacardiovascularchronic kidney diseaseiron deficiencysodium-glucose cotransporter 2 inhibitors

Substanzen

CanagliflozinIronSodium-Glucose Transporter 2 InhibitorsBiomarkers

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Department of Nephrology and Rheumatology, Kanazawa University, Ishikawa, Japan.
  • The George Institute for Global Health, UNSW Sydney, Sydney, Australia.
  • Department of Nephrology, St George Hospital, Sydney, Australia.
  • Faculty of Medicine, University of New South Wales, Sydney, Australia.
  • Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia.

ORCID-Profile: Akihiko Koshino, Hiddo J L Heerspink, Clare Arnott, Carol Pollock, Brendon L Neuen

Förderung

  • Janssen Research and Development
  • Mitsubishi Tanabe Pharm

Zitieren

APA

Koshino, A., Heerspink, H. J. L., Jongs, N., Badve, S. V., Arnott, C., Neal, B., Jardine, M., Mahaffey, K. W., Pollock, C., Perkovic, V., Hansen, M. K., Bakker, S. J. L., Wada, T., & Neuen, B. L. (2025). Canagliflozin and iron metabolism in the CREDENCE trial. Nephrology Dialysis Transplantation, 40(4), 696-706. https://doi.org/10.1093/ndt/gfae198

Vancouver

Koshino A, Heerspink HJL, Jongs N, Badve SV, Arnott C, Neal B, et al. Canagliflozin and iron metabolism in the CREDENCE trial. Nephrology Dialysis Transplantation. 2025;40(4):696-706. doi:10.1093/ndt/gfae198

BibTeX
@article{Koshino2025,
  author = {Koshino, Akihiko and Heerspink, Hiddo J L and Jongs, Niels and Badve, Sunil V and Arnott, Clare and Neal, Bruce and Jardine, Meg and Mahaffey, Kenneth W and Pollock, Carol and Perkovic, Vlado and Hansen, Michael K and Bakker, Stephan J L and Wada, Takashi and Neuen, Brendon L},
  title = {Canagliflozin and iron metabolism in the CREDENCE trial},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  volume = {40},
  number = {4},
  pages = {696--706},
  doi = {10.1093/ndt/gfae198}
}
Kostenlos starten →